leisure time -WSS

leisure time

author：leisure time 2025-09-07 04:06:56 - browse：46

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： How generative AI is inspiring dreams of a health data revolution

WSS

A rare thyroid diagnosis led to unexpected, all

Ethical issues complicate the benefits of medical crowdfunding

Syphilis numbers in the United States reach record heights

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Amazon on where the company's health care bets are headed next

Illumina names Agilent executive as new CEO

knowledge

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

Medicare Advantage insurers face 0.2% cut to 2025 payments

Medicare details structure of new drug price negotiation program

FTC sues over Novant Health acquisition of two N.C. hospitals

What does generative AI mean for health care? We asked experts

How to protect patients from sexual assault

Tori Bowie and the unacceptable rates of Black maternal death

FTC sues over Novant Health acquisition of two N.C. hospitals

New air purifier tech could be key to improving indoor air quality

What American doctors can learn from their Israeli counterparts

knowledge

Amazon on where the company's health care bets are headed next

Listen: Biogen's potential pivot, & Illumina's next chapter

Medicaid rebukes states for mistakenly disenrolling children

Ethical issues complicate the benefits of medical crowdfunding

Why Novartis is changing the name of its research labs

Ethical issues complicate the benefits of medical crowdfunding

focus

leisure time

Wikipedia

leisure time